Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
7.56M
-
Shares change
-
-1.04M
-
Total reported value, excl. options
-
$87.6M
-
Value change
-
-$11.8M
-
Number of buys
-
23
-
Number of sells
-
-18
-
Price
-
$11.59
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q1 2021
53 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q1 2021.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.56M shares
.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (3.22M shares), Polaris Venture Management Co. V, L.L.C. (1.1M shares), Ikarian Capital, LLC (781K shares), Soleus Capital Management, L.P. (476K shares), BlackRock Inc. (348K shares), VANGUARD GROUP INC (212K shares), JPMORGAN CHASE & CO (147K shares), ArrowMark Colorado Holdings LLC (139K shares), MORGAN STANLEY (107K shares), and STATE STREET CORP (96.2K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.